Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2005-09-27
2005-09-27
Park, Hankyel T. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S006120, C435S069100, C435S173300, C435S339100, C435S974000, C530S300000, C530S350000, C800S003000, C800S018000, C800S025000
Reexamination Certificate
active
06949337
ABSTRACT:
The present invention provides methods of identifying anti-HIV compound by contacting human Vpr Interacting Protein (hVIP), or a fragment thereof known to interact with Vpr, with Vpr, or a fragment thereof known to interact with hVIP in the presence of a test compound, and comparing the affinity of the hVIP or fragment thereof to the Vpr or fragment thereof in the presence of the test compound with the affinity of the hVIP or fragment thereof to the Vpr or fragment thereof in the absence of the test compound. The present invention also provides transgenic non-human mammals comprising a recombinant expression vector that comprises a nucleic acid sequence that encodes hVIP.
REFERENCES:
patent: 4736866 (1988-04-01), Leder et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 5001230 (1991-03-01), Brown et al.
patent: 5108921 (1992-04-01), Low et al.
patent: 6060587 (2000-05-01), Weiner et al.
patent: 6448078 (2002-09-01), Weiner et al.
Adachi, et al., “Production of Acquired Immunodeficiency Syndrome: Associated Retrovirus un Human and Nonhuman Cells Transfected with an Infectious Molecular Clone,” J. Virol. (1986) 59:284-291.
Aguanno, et al., “12-O-Tetradecanoylphorbol-13-Acetate-induced Differentiation of a Human Rhabdomyosarcoma Cell Line,” Cencer Res. (1990)50:3377-3382.
Arya, et al., “Trans-Activator Gene of Human T-Lymphocyte Virus Type III (HTLV-III),” Science (1985) 229-69-73.
Balliet, et al., “Distinct Effects in Primary Macrophages and Lymphocytes of the Human Immunodeficiency Virus Type I Accessory Genes vpr, vpu, and nef: Mutational Analysis of a Primary HIV-I Isolate,” Virology (1994)200:623-631.
Balotta, et al., “Antisense Phosphorothioate Oligodeoxynucleotides Targeted to the vpr GeneInhibit Immunodeficiency Virus Type I Replication in Primary Human Macrophages,” J. Virol. (1993) 67:4409-4414.
Chantal Petit, et al., “Human Immunodeficiency VirusInfection Down-Regulates HLA Class II Expression and Induces Differentiation inPromonocytic U937 Cells,” J. Clin Invest. (1987) 79:1883-1889.
Cohen, et al., “Human Immunodeficiency Virus vpr Product is a Viron-Associated Regulatory Protein,” J. Virol. (1990) 64:3097-3099.
Cohen, et al., “Identification of HIV-Ivpr Product and Function,” J. AIDS (1990) 3:11-18.
Colmenares, et al., “The ski Oncogene Induces Muscle Differentiation in Quail Embryo Cells,” Cell(1989) 59:293-303.
Connor, et al., “Vpr is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes,” Virology (1995) 206:935-944.
Dedera, et al., “Viral Protein R of Human Immunodeficiency Virus Types 1 and 2 is Dispensible for Replication and Cytopathogenecity in Lymphoid Cells,” J. Virol. (1989) 63:3205-3208.
DiMarzo, et al., “Mutational Analysis of Cell Cycle Arrest, Nuclear Localization, and Virion Packaging of Human Immunodeficiency Virus Type I Vpr,” J. Virol. (1995) 69:7909-7916.
Draper, et al., “CCR4 is a Glucose-Regulated Transcription Factor Whose Leucine-Rich Repeat Binds Several Proteins Important for Placing CCR4 in its Proper Promoter Context,” Mol. Cell. Biol. 1994) 14:4522-4531.
Dubiel, et al., “Molecular cloning and expression of subunit 12:a non-MCP and non-ATPase subunit of the 26S protease,” FEBS Lett. (1995) 363:97-100.
Fields, et al., “A Novel Genetic System to Detect Protein-Protein Interactions,” Nature (1989) 340-245-246.
Fields, et al., “The Two-Hybrid System to Detect Protein-Protein Interactions,” Methods: A Companion to Methods in Enzymology (1993) 5:116-124.
Fields, et al., The Two-Hybrid System: An Assay for Protein-Protein Interactions, Trends in Genetics, Aug 1994, 10(8)286-292.
Fisher, et al., “A molecular clone of HTLV-III with biological activity,” Nature (1985) 316:262-265.
Flethcher, et al., “Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV-sm,” EMBO J. (1996) 15:6155-6165.
Fuerst, et al., “Use of a Hybrid Vaccina Virus-T7 RNA Polymerase System for Expression of Target Genes,” Mol. Cell. Biol. (1987) 7:2538-2544.
Gallo, et al., “Frequent Detection and Isolation of Cytopathic Retrovirus (HTLV-III) from Patients with AIDS and at Risk for AIDS,” Science (1984) 224:500-503.
Garrett, et al., “Rev Activates Expression of the Human Immunodeficiency Virus Type 1 vif and vpr Gene Products,” J. Virol.(1991) 65:1653-1657.
Gras-Masse, et al., “A Synthetic Protein Corresponding to the Entire VPR Gene Product from the Human Immunodeficiency Virus HIV-1 is Recognized by Antibodies form HIV-Infected Patients,” Intl. J. Peptide Protein Res. (1990) 36:219-226.
Gridley, et al., “Molecular Analysis of the Move 34 Mutation: Transcript Disrupted by proviral Integration in Mice is Conserved in Drosophila,” Development (1990) 109:235-242.
Gridley, et al., “The murine Mov-34 gene: Full length cDNA and genomic organization,” Genomics (1991) 11:501-507.
Griffin, et al., “Activation of HIV gene expression during monocyte differentiation by induction of NF-kappaB,” Nature (339) 70-73.
Frigerio, et al, “Cloning, sequencing and expression of the L5, L21, L27a, L28, S5, S9, S10 and S29 human ribosomal protein mRNAs,” Biochim. Biophys. Acta (1995) 1262:64-68.
Harada, et al., “Tumor Promoter, TPA, Enhances Replication of HTLA-III/LAV,” Virology (1986) 154:249-258.
Hattori, et al., “The human immunodeficiency virustype 2 genesis essential for production infection of human macrophages,” Proc. Natl. Acad. Sci. USA (1990) 87:8080-8084.
He, et al., “Human Immunodeficiency Virus Type 1 Viral Protein R (Vpr) Arrests Cells in the G2 Phase of the Cell Cycle by Inhibiting p34-cdc2 Activity,” J. Virol. (1995) 69(11):6705-6711.
Heinzinger, et al., “The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells,” Proc. Natl. Acad. Sci. USA (1994) 91:7311-7315.
Hiti, et al., “Expression of the MyoD1 Muscle Determination Gene Defines Differentiation Capability but not Tumorigenicity of Human Rhabdomyosarcomas,” Mol. Cell Biol. (1989) 9(11):4722-4730.
Ho, et al., “Site-Directed Mutagenesis by Overlap Extension Using the Polymerase chain Reaction,” Gene (1989) 77:51-59.
Jowett, et al., “The Human Immunodeficiency Virus Type 1 vpr Gene Arrests Infected T Cells in the G2 + M Phase of the Cell Cycle,” J. Virol. (1995) 69:6304-6313.
Kent, et al., Synthetic Peptides in Biology and Medicine (1985) Alioto, et al, eds., Elsevier Science Publishers, Amsterdam, p. 29-57.
Korber, et al., “Signature Pattern Analysis: A Method for Assessing Viral Sequence Relatedness,” AIDS Res. Human Retrovirus (1992) 8(9):1549-1560.
Kozak, M., “Point Mutations Define a Sequence Flanking the AUG Initiator Codon that Modulates Translation by Eukaryotic Ribosomes” Cell (1986) 44:283-292.
Levy, et al., “Induction of Cell Differentiation by Human Immunodeficiency Virus 1 vpr,” Cell (1993) 72:541-550.
Levy, et al, “Extracellular Vpr Protein Increases Cellular Permissiveness to Human Immunodeficiency Virus Replication and Reactivates Virus from Latency,” J. Virol. (1995) 69(2): 1243-1252.
Levy, et al., “Isolation of Lymphocytopathic Retrovirus from San Francisco Patients with AIDS,” Science (1984) 225:840-842.
Li, et al, “Human Immunodeficiency Virus Type 1 DNA Synthesis, Integration, and Efficient Viral Replication in Growth Arrested T Cells,” J. Virol.(1993) 67:3969-3977.
Ling, et al., “Optimization of the Polymerase Chain Reaction with Regard to Fidelity: Modified T7, Taq, and Vent DNA Polymerases,” PCR Methods and Applications (1991) 1:63-69.
Lu, et al., “Human Immunodefi
Ayyavoo Velpandi
Mahalingam Sundarasamy
Patel Mamata
Weiner David B.
Cozen O'Connor P.C.
Park Hankyel T.
The Trustees of the University of Pennsylvania
LandOfFree
Cellular receptor for HIV-1 Vpr essential for G2/M phase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cellular receptor for HIV-1 Vpr essential for G2/M phase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cellular receptor for HIV-1 Vpr essential for G2/M phase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3382110